Palifermin is recombinant human keratinocyte growth factor. This stimulates proliferation of keratinocytes and the epithelial cells lining mucosal surfaces.
Patient selection: Autologous or allogeneic HSCT with myeloablation and total body irradiation (TBI). It is not recommended if only chemotherapy is given. It is not recommended to prevent oral mucositis in other situations.
Dose: 60 µg/kg per day infused intravenously
Regimen:
(1) The first palifermin infusion is given IV on day 1.
(2) The second palifermin is given IV on day 2.
(3) The third palifermin is given IV on day 3.
(4) Myelotoxic regimen is started 24 to 48 hours later (day 4 to 6, depending on when the third palifermin infusion is given). The number of days for the myelotoxic regimen may vary.
(5) The HSCT infusion is given 24 hours after myelotoxic regimen is completed. The fourth palifermin infusion is given the same day after the HSCT infusion. There should be 4 or more days between the start of this dose and the third palifermin dose given on day 3.
(6) The fifth palifermin infusion is given on the following day.
(7) The sixth and final palifermin infusion is given on the day after the fifth infusion.
